New research reveals that intermittent fasting can significantly enhance the effectiveness of oestrogen-blocking breast ...
The SERD improved survival endpoints compared to standard adjuvant endocrine therapy in a Phase III trial that may support ...
Among more than 4,000 patients with hormone receptor (HR)-positive disease, 3-year invasive disease-free survival (IDFS) ...
Giredestrant significantly improved IDFS in ER-positive, HER2-negative early breast cancer, reducing recurrence or death risk by 30% compared to SOC endocrine therapy. Subgroup analyses showed ...
Aromatase inhibitors demonstrated superior disease-free survival and time to distant recurrence compared to SERMs in HR+/HER2+ early breast cancer. The benefits of aromatase inhibitors were consistent ...
In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...
In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant ...
Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...
In premenopausal women with non-metastatic breast cancer, use of tamoxifen may nearly double the risk of endometrial cancer, researchers report.
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback